Why are biotech stocks down today

Shares of Moderna (NASDAQ:MRNA) are down 11% at 12:39 p.m. EST after the company priced its secondary offering at $19 per share, allowing the biotech to raise approximately $500 million. The IBD’s coverage of the biotech stock news and pharma stocks today keeps you on top of these fast-moving companies. Today’s laggard could be a biotech stock to watch tomorrow. Investors are again worried about a biotech bubble as biotech stocks take another big hit this week. Since April 23, the Nasdaq Biotechnology Index has dropped 6.8%. During the same time, the S&P Biotechnology Industry Index is down 8.5%.

IBD's coverage of the biotech stock news and pharma stocks today keeps you on top of these fast-moving companies. Today's laggard could be a biotech stock  Inovio Pharmaceuticals Inc (NASDAQ: INO) stock is on a volatile up-and-down ride as investors appear uncertain about its claims regarding a breakthrough in the  15 Jan 2020 While the S&P 500 rose 30% during the year, many biotech stocks soared much higher. for a correction, whether it's this year or sometime down the road. valuations and neglect how much a company has proven today. Latest news for pharmaceuticals, biotechnology and life sciences. Coronavirus updates: Fed slashes rates to shore up economy, US stock futures plunge S&P 500 recovers some of its steep losses after halt, now down 8%. 2. Coronavirus 

Investors are again worried about a biotech bubble as biotech stocks take another big hit this week. Since April 23, the Nasdaq Biotechnology Index has dropped 6.8%. During the same time, the S&P Biotechnology Industry Index is down 8.5%.

Shares of tiny biotech iBio Inc. surged another 19% in premarket trade Thursday, on continued strong hopes for its partnership with a Chinese company on a plant-based vaccine to treat the coronavirus. Biotech stocks fell into one of the deepest craters in their history, starting last summer, but rumblings of a recovery are sounding. After a three-year bull run that more than quadrupled its value by its peak last July, IBD's Medical-Biomed/Biotech Industry Group plunged 50% by early February, Zai Lab (NASDAQ: ZLAB) is a Chinese biotech that launched in 2014. But today, it has a $2.6 billion market cap. That’s some pretty fast growth. 2019 has not been a great year to own biotech stocks (so far). Since the year began, the Nasdaq Biotechnology Index (NBI) is down more than six percentage points, against near 16% rise for the S&P Why Is Biotech Down and Will It Stay That Way? Chelsea Pratt - September 14th, 2016 Fortune magazine reported that biotech stocks have fallen 25 percent this year, and with numbers that Shares of Moderna (NASDAQ:MRNA) are down 11% at 12:39 p.m. EST after the company priced its secondary offering at $19 per share, allowing the biotech to raise approximately $500 million. The

Ajooni Biotech Share Price Live - 8.35, Ajooni Biotech Stock Price, Today - The Economic Times.

2019 has not been a great year to own biotech stocks (so far). Since the year began, the Nasdaq Biotechnology Index (NBI) is down more than six percentage points, against near 16% rise for the S&P Biotech stocks continue to exhibit signs of weakness and are signaling that they are heading lower. After being up by 11 percent through the end of January, the group has deteriorated, and is presently up about 4 percent using the Nasdaq Biotech (IBB) as a proxy.

Inovio stock rallies after company gets Gates Foundation grant to test device for coronavirus vaccine · DJIA 5.20%. Mar. 14, 2020 at 10:18 a.m. ET by Ciara 

What is Oncolytics Biotech's stock price today? One share of ONCY stock can currently be purchased for approximately $1.10. How big of a company is Oncolytics  6 May 2016 Biotech stock indices have fallen nearly five times as much as the broader Biotechnology Index (IBB) and the S&P Biotech ETF (XBI) down 

27 Mar 2001 Investors are accustomed to watching biotechnology stocks rise and fall to bring the sky-high valuations of biotech firms quickly down to earth, Today, they trade at 50 times 2001 earnings, according to research done by.

American Stock Exchange Biotechnology Index. is down 25% for the year, after posting big gains over the past two years. Genomic stocks have been hit the hardest, with companies like Arcadia's stock has now gained 15.6% over the past 12 months, while the iShares Nasdaq Biotechnology ETF has lost 10.2% and the S&P 500 has edged up 2.2%. Arcadia's stock was back up toward levels last seen during the February-March rally, which was on the back Shares of Puma Biotechnology (NASDAQ: PBYI), a small-cap cancer company, are absolutely on fire this morning. Specifically, the biotech's shares gained as much as 38% right out of the gate Wednesday.

Shares of tiny biotech iBio Inc. surged another 19% in premarket trade Thursday, on continued strong hopes for its partnership with a Chinese company on a plant-based vaccine to treat the coronavirus. Biotech stocks fell into one of the deepest craters in their history, starting last summer, but rumblings of a recovery are sounding. After a three-year bull run that more than quadrupled its value by its peak last July, IBD's Medical-Biomed/Biotech Industry Group plunged 50% by early February, Zai Lab (NASDAQ: ZLAB) is a Chinese biotech that launched in 2014. But today, it has a $2.6 billion market cap. That’s some pretty fast growth. 2019 has not been a great year to own biotech stocks (so far). Since the year began, the Nasdaq Biotechnology Index (NBI) is down more than six percentage points, against near 16% rise for the S&P Why Is Biotech Down and Will It Stay That Way? Chelsea Pratt - September 14th, 2016 Fortune magazine reported that biotech stocks have fallen 25 percent this year, and with numbers that